Abstract. Conventional risk factors have limited ability to predict recurrent events in subjects with first-time coronary artery disease (CAD). This aim of this study was to identify novel biomarkers using comparative global proteome analysis to improve the risk assessment for recurrent coronary events. We used samples from phase-I of the Indian Atherosclerosis Research Study (IARS), consisting of 2,332 subjects, of whom 772 were CAD-affected subjects, including 152 with recurrent events identified during a 5-year follow-up period. Global proteome analysis was performed on serum samples of 85 subjects with recurrent coronary events and 85 age-and gender-matched subjects with first-time CAD using surfaceenhanced laser desorption ionization time-of-flight mass spectrometry with CM10 arrays. TagIdent was used for protein identification followed by validation by western blot analysis and ELISA. Data were analyzed by logistic analysis, Cox-regression, hazards ratio, C-statistics and combined-marker risk score using SPSS version-17 and R-package version-2.13.0 software. We identified 16 significantly differentially expressed protein peaks. Of these, 2 peaks corresponding to m/z 8588 and 1864 were identified as β-defensin-128 and histatin-3, belonging to the danger-recognizing peptide family, which exhibited a significant independent association with recurrent events (odds ratios of 7.49 and 1.4, respectively). C-statistics improved significantly from 0.677 for conventional risk factors alone to 0.800 (p-value=0.001) in combination with β-defensin-128 and histatin-3 with a hazards ratio of 1.833. A combined risk score of β-defensin-128 and histatin-3 could reclassify 112 out of the 170 subjects into intermediate-and high-risk groups. On the whole, our data indicate that β-defensin-128 and histatin-3 may be potential biomarkers whch may be used to improve risk the stratification for recurrent coronary events.
Introduction
Cardiovascular diseases have reached epidemic proportions in India, particularly among the younger population in comparison to other ethnic groups (1) . Patients who have survived a first-time coronary event are at a greater risk of developing recurrent episodes, as compared to asymptomatic subjects (2) . Several biomarkers belonging to different pathways have been identified in coronary artery disease (CAD) and are being deployed to identify the subset of subjects who are at a greater risk of developing acute coronary events. These biomarkers are associated with inflammation (C-reactive protein), hemodynamic stress (brain natriuretic peptide, N-terminal prohormone brain natriuretic peptide) and kidney dysfunction (albuminuria andcystatin-C) (3, 4) . Pathogen burden caused due to the simultaneous infection by multiple pathogens, such as Chlamydia pneumoniae, cytomegalovirus (CMV), Helicobacter pylori, Herpes simplex virus (5) and in particular, neutralizing antibody titers against CMV along with inflammatory markers have been shown to be important for risk stratification in the Asian Indian population (6) .
On the other hand, the use of global proteome analysis can not only provide a better understanding of the underlying disease process, but can also help to unearth novel disease markers that can enhance the power to predict the risk of acute coronary events when combined with other well-studied markers as discussed above (7) . This includes the comparative proteomics approaches based on mass spectrometric analysis of protein profiles in serum samples obtained from normal and diseased subjects. Therefore, the aim of this study was to perform global proteome analysis using the surface-enhanced laser desorption ionization timeof-flight mass spectrometry (SELDI-TOF MS) platform to possibly identify novel biomarkers associated with recurrent coronary events in patients with established CAD. We identified 2 infection-related proteins, namely β-defensin-128 and histatin-3 as potential biomarkers for recurrent CAD. A total of 152 subjects from this CAD-affected group experienced a recurrence of cardiac events during the course of a 5-year follow-up period. All the subjects in this study had a family history of CAD, and we matched the age and gender of 85 subjects in the recurrent events group to those of 85 subjects with first-time events, and the serum samples of these subjects was used for global proteome analysis. The baseline characteristics of the study participants are presented in Table I . The subjects were recruited based on the following criteria: i) age at onset of CAD was ≤60 years for males and ≤65 years for females; ii) the diagnosis of CAD was based on an electrocardiogram (ECG)/echocardiography (echo)/biochemical or angiogram findings; iii) patients who were posted for percutaneous transluminal coronary angiography (PTCA)/ coronary artery bypass graft (CABG). The subjects who did not meet the above-mentioned criteria or had any other major illness, as defined by the World Health Organization, such as cancer, liver failure, etc. were excluded from the study. All blood samples were collected after overnight fasting for 12-14 h, and the plasma and serum aliquots were stored at -80˚C. Detailed information on medical history, demographics and relevant information, including 3-generation pedigree was recorded in a questionnaire after a personal interview. The diagnosis of diabetes and hypertension was based on medical reports, while the body mass index was calculated.
Danger-recognizing proteins, β-defensin-
Telephonic assessment of cardiac health status. The periodic telephonic follow-up of all study participants was undertaken to obtain an update on the cardiac health status and 5 such rounds of follow-up were completed. Follow-up was performed once every 18 months on an average from the time of recruitment with a successful follow-up rate of 60%. Endpoints included non-fatal events (re-do PTCA/re-do CABG/heart attack, stroke) and fatal events (fatal heart attack/fatal stroke/sudden death/cardiac arrest). This information was verified through either paper trail or hospital records whenever available.
Global proteome analysis. Global proteome analysis of serum samples was performed using SELDI-TOF MS. Sinapinic Acid (SPA) and CM10 chip were purchased from Bio-Rad (Hercules, CA, USA) and all the other reagents were from Sigma-Aldrich (St. Louis, MO, USA). Serum samples were assayed on CM10 chip and data were analyzed using Ciphergen Express Client software. Serum samples were thawed on ice and centrifuged at 14,000 rpm for 5 min at 4˚C. A total of 20 µl of supernatant and 30 µl of U9-buffer (9 M urea, 2% CAHPS, 1% DTT) were added to a tube and agitated for 30 min at 4˚C on a platform shaker. Subsequently, 450 µl of Tris-HCl (50 mM pH 7.5) were added to the U9/serum mixture and agitated at 4˚C for 2 min. This was followed by the addition of 150 µl of 50 mM Tris-HCl (pH 7.5) and agitation for 5 min twice to activate the CM10 chips. Diluted samples (150 µl) were spotted onto a bio-processor containing the ProteinChip arrays and then agitated on a platform shaker for 60 min at room temperature. Excess serum was discarded and the chips were washed thrice with 150 µl of Tris-HCl (50 mM, pH 7.5) and twice with 200 µl of dH 2 O, removed from the bioprocessor and air-dried.
Prior to SELDI analysis, 1 µl of a saturated solution of SPA was applied onto each chip twice and air-dried.
Analysis of protein chip array and protein identification.
A set of different protocols was used on each spot which varied in laser intensity. Pre-processing was done on ProteinChip © software 3.1. Peaks which had less background noise were considered for further analysis after baseline subtraction. The peaks were normalized and those having ±2 standard deviation were removed. Finally, clusters were made by expression differential matrix (EDM) within a range of 1,500-30,000 Da. Peaks having m/z <1,500 were considered as matrix noise. A threshold of 20% and signal to noise ratio and valley depth of 5 was set as first pass and 0.3% mass window and second pass of 2 was assigned. Mass accuracy was calibrated to <0.1% by all-in-one peptide molecular mass standard (Ciphergen Biosystems, Fremont, CA, USA).
Biomarker validation assays. Three independent western blot analyses were performed to validate the presence and levels of significant proteins identified through global proteome analysis. Age-and gender-matched serum samples from 10 CAD-affected and 10 CAD patients with recurrent events were used for western blot analysis. An equal amount of 50 µg protein was loaded after protein estimation using the Bradford method. The blot was first probed for β-defensin-128 (sc-51670, secondary antibody SC-2033; Santa Cruz Biotechnology, Inc., Santa Cruz, Ca, USA) and then re-probed with histatin-3 antibody (SAB1402234; Sigma-Aldrich; secondary antibody sc-2005; Santa Cruz Biotechnology, Inc.). Finally, the same blot was probed for loading control β-tubulin (sc-85539; Santa Cruz Biotechnology, Inc.). Following 3 independent western blot analyses, the images were scanned in Bio-Rad molecular imaging ChemiDoc XRS plus (Bio-Rad), and bands were quantified using ImageJ software (http://rsbweb.nih.gov/ij/index.html) and ratio of β-defensin-128/β-tubulin and histatin-3/β-tubulin were calculated (Fig. 2B ). ELISAs were performed for β-defensin-128 (CSB-EL006698HU) and histatin-3 (CSB-EL006698HU) using kits from Cusabio (Hubei, China) with covariance percentage of 1.21 and 7.04%, respectively.
Bioinformatics and statistical analysis. We compared the differential pattern of protein levels between the first-time CAD-affected group and the recurrent event group. Prior to the analyses, all spectra were normalized, and subjected to baseline correction and de-noising. A non-parametric t-test (Mann-Whitney) was performed to identify the most significant peaks. TagIdent software (www.expasy.org) was used to identify the proteins from their corresponding m/z values (Table IIA) (9) (10) (11) (12) . Backward logistic regression, logistic regression, Cox regression analysis for hazards ratio (HR) and C-statistics were performed for the ELISA data to estimate the improvement in risk assessment of the predictive models using the two biomarkers. Using the probabilities scores through logistic regression followed by ROC analysis, we generated the area under the receiver operating characteristic curve (AUC) for 3 different models: conventional risk factors (CRFs) [age, gender, hypertension (HTN), diabetes mellitus (DM), body mass index (BMI), waist-hip ratio, smoking, total cholesterol (TC), triglycerides (TG), high-density lipoprotein (HDL) and low-density lipoprotein (LDL)] alone, the biomarkers alone, and for a combination of CRFs and biomarkers. The significance of improvement or change in the models was calculated using the DeLong method. The combined risk score was calculated for the final model of biomarkers values adjusted to CRFs. We used the following equation to calculate the combined risk score for these two biomarkers (13): combined score = (β1xβ -bi omarker1) + (β2xbiomarker2) where, β1 and β2 denote the estimates of biomarker 1β coefficient (β-defensin-128) and biomarker 2 (histatin-3), respectively. Participants were categorized into quintiles of combined risk score with the lowest two quintiles categorized as low risk, third and fourth quintiles as intermediate, and the top quintile as high risk categories. The Kaplan-Meier curve analysis was performed for the best models for estimating the cumulative cardiovascular events in each group and plots were generated for the low and high risk groups. The analysis was performed using SPSS software (version 17.0) and R package 2.13.0.
Results
Patient characteristics. Table I shows the clinical characteristics of the study participants. The mean age, gender distribution, BMI and lipid profile were comparable between the patients with firsttime CAD and those with recurrent events. Hypertension and a higher systolic blood pressure were more frequent, and LDL-c levels were higher in the latter group than in the former group of patients. The subgroup with recurrent events included 21 deaths due to cardiac arrest out of 85 subjects, while none of the patients in the first-time CAD-affected group had any event or death.
Protein profiling. The proteomic profile of the 85 first-time CAD-affected and 85 subjects with recurrent events using SELDI-TOF MS yielded 39 differentially expressed protein peaks [representative peak and pseudo gel ( Fig. 1) ], of which 16 had p-values <0.05 (Table IIA) HTN-3) , respectively, to be significantly associated with odds ratios of 7.49 (95% CI, 2.71-21.90, p-value <0.001) and 1.4 (95% CI, 1.02-2.13, p-value=0.042), respectively (Table IIB) . These markers were further used for validation.
Biomarker validation. The two protein peaks, m/z 8588 and m/z 1864, corresponding to β-defensin-128 and histatin-3 were validated using western blot analysis ( Fig. 2A) . Densitometric analysis (Fig. 2B ) of the protein bands suggested that the levels of both proteins were higher in subjects with recurrent events than in the subjects with first-time CAD. Furthermore, ELISAs (Fig. 2C ) performed for these two proteins in all the 170 subjects confirmed that both proteins were significantly differentially expressed. The mean levels of β-defensin-128 in the first-time CAD-affected subjects was 0.779±0.045 ng/ ml and in the recurrent subjects was 1.19±0.082 ng/ ml (p-value=2.2x10 -15 ). Similarly, the histatin-3 level was 2.38±0.130 µg/ml in the first-time CAD affected subjects and 3.42±0.306 µg/ml in the recurrent subjects (p-value of 0.002).
Association of β-defensin-128 and histatin-3 in CAD-affected subjects with recurrent events.
We evaluated individual and combined association of these biomarkers with recurrent events. As shown in Table III , the HR for β-defensin-128 was 1.715 (95% CI, 1.32-2.24; p-value=8.14x10 -5 ) and that for histatin-3 was 1.133 (95% CI, 1.04-1.24; p-value= 0.004).
However, when combined with the CRFs, the HRs improved to 1.729 (95% CI, 1.28-2.34; p-value=3.51x10 -4 ) for β-defensin-128 and 1.147 (95% CI, 1.04-1.26; p-value= 0.004) for histatin-3. The combined HR of β-defensin-128 and histatin-3 together was 1.699 (95% CI, 1.29-2.24; p-value=1.6x10 -4 ) before adjustment and 1.833 (95% CI, 1.34-2.50; p-value=1.3x10 -4 ) after adjustment for the conventional risk factors. The analysis of C-statistics (Fig. 3) suggested that CRFs alone yielded an AUC of 0.677 (95% CI, 0.601-0.714; p-value=5.1x10 -5 ). Upon the addition of biomarkers, the AUC increased to 0.800 (95% CI, 0.702-0.844; p-value=1.37x10 -9 ) and the difference was statistically significant (p-value=0.001) (Table IV) as evaluated using DeLong analysis.
The combined risk score (Table V) ). The analysis of the complete study group (n=170) revealed that 81 subjects were at high risk of which 31 belonged to the CAD-affected group and 51 were subjects with recurrent events (13 deaths and 3 subjects with a third reported event). Similarly, 32 subjects were reclassified into the intermediate risk group, of which 17 were from the affected group, while 15 belonged to the recurrent events group (3 deaths and 2 subjects with 3 events reported). Kaplan- Meier survival analysis for the cumulative probability of recurrent event for the model containing β-defensin-128 and histatin-3 adjusted to the CRFs, suggested that subjects in the high-risk group had a low survival rate as compared to those in the low-risk group (Fig. 4A) . Similar analysis on the cumulative probabilities of death due to cardiovascular events or occurrence of triple events for recurrent event subjects alone also suggested that the high-risk group had a low survival rate as compared to the low-risk subjects (Fig. 4B) .
Discussion
Using comparative global proteome analysis, we identified β-defensin-128 and histatin-3 as novel biomarkers associated with recurrent coronary events. Recently, we also demonstrated that pathogen burden (5) and in specific CMV-NA titer is strongly associated with recurrent CAD events (6) . Several other studies have focused on using putative candidate biomarkers for improving risk assessment in cases with recurrent CAD events, and these have provided a modest improvement in the risk discrimination (4). These findings suggest that there is a need to improve these discriminative models, as it is well known that subjects with established CAD have a high risk of further vascular events compared to disease-free subjects (14) . In such a scenario, the use of global proteomic analysis help to unearth newer biomarkers that can substantially improve risk assessment. Global proteome analysis using SELDI-TOF MS commonly used for biomarker discovery in complex diseases has also been described with regard to network biomarkers associated with the incidence of CAD (15) , major adverse cardiac events (MACE) (16) and the identification of soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) as a possible biomarker of subclinical atherosclerosis (17) .
Of the 16 significant peaks (Table IIA) , logistic regression analysis identified 2 significantly associated proteins, β-defensin-128 and histatin-3 (Table IIB) . Furthermore, western blot analysis ( Fig. 2A and B) and ELISAs (Fig. 2C ) in individual serum samples also revealed differential levels of these proteins in the 2 groups. β-defensins play an important role in immunoregulation (18) , and have been shown to be significantly associated progressive cardiovascular disease (19) . Furthermore, genetic polymorphisms and copy number variation of β-defensin-4 gene have been shown to be associated with ischemic stroke (20) . Other studies have shown that in oral infections by spirochetes, which constitute 40% of the microflora in disease sites, are also linked to cardiovascular diseases (21, 22) . In our analysis, β-defensin-128 was shown to be associated with recurrent events, suggesting that this may be a novel biomarker belonging to the defensin family, linking infection and immunity to CAD. Similarly, gene polymorphisms in histatin-3 (23) and gene expression (24) have been shown to play a major role in oral and other infections.
Of the other proteins identified (Table IIA) , we found peptides, such as natriuretic peptide-B, pro-neuropeptide-Y and peptide-YY which are associated with cardiovascular diseases (25) . However, in the present study, infection-related biomarkers, β-defensin-128 and histatin-3 in particular seem to play a major role in the discrimination between firsttime CAD-affected subjects and those with recurrent events (Tables III-V and Figs. 3 and 4) . This may be due to the importance of active infection of CMV in these subjects, as our previous study using the same subset of patients demonstrated that higher titer values of CMV-NA (6) were associated with first-time CAD and to recurrent CAD (26) .
Several studies have shown that chronic infection can lead to pro-atherogenic effects (27) , and can lead to vascular damage (27) (28) (29) . The Asian population has been earlier reported to have a higher pathogen burden, which includes CMV infection (5, 6, 26) and the identification of these two biomarkers suggests that they may add better value proposition in conjunction with other biomarkers. Earlier studies have reported that the combination of biomarkers, such as Nt-proBNP, albuminuria and CRP (4) or CMV-NA with IL-6 (6) has a marginal improvement in C-statistics. Therefore, the development of a multimarker approach by including β-defensin-128 and histatin-3, where there was a significant improvement in the AUC (Table IV) , may help to better discriminate subjects with recurrent CAD. Furthermore, the combined risk scores of β-defensin-128 and histatin-3 (Table V) and Kaplan-Meier curve cumulative probability analysis of cardiovascular events (Fig. 4A) or deaths/3rd event (Fig. 4B) suggested that 68 out of the 85 subjects with recurrent events were correctly classified into the intermediate-and high-risk groups. Kaplan-Meier curve of the cumulative probability of cardiovascular recurrent events in accordance with different risk categories using a combined score of histatin-3 and β-defensin-128 adjusted to the conventional risk factors in a 5-year follow-up study in 85 subjects with recurrent events. (B) Kaplan-Meier curve of the cumulative probability of cardiovascular death and third event in the recurrent events subjects in low-and high-risk categories using a combined risk score of histatin-3 and β-defensin-128, adjusted to conventional risk factors (CRFs). Understanding the limitations of the present study, further validation of these biomarkers in larger cohort of subject is needed. In order to understand the role of other proteins, protein-protein interactions network (15) , pathways, regulome analysis (30) and greater dissection of all the 16 significant proteins in our data set (Table IIA) may provide a comprehensive understanding of the crosstalk that occurs among the different pathways and their collective contribution to recurrent coronary events.
In conclusion, this study identified two members of the danger-recognizing protein family, β-defensin-128 and histatin-3 which are associated with recurrent CAD events, and also demonstrated their potential use in discrimination of subjects.
